Composition, form of production and packaging
? Tablets for resorption of flat-cylindrical shape, with a risk and chamfer, from white to almost white. On the flat side, the inscription MATERIA MEDICA is painted with a risk, on the other flat side there is inscription DIVAZA.
antibodies to the brain-specific protein S-100 0.006 g *
antibodies to endothelial NO synthase 0.006 g *
* are applied to lactose in the form of a mixture of three active hydroalcoholic dilutions of the substance diluted 100-12, 100 30 , 100 200 times, respectively.
Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.
20 pcs. - Cellular outline packaging (aluminum / PVC) (1) - cardboard packs.
20 pcs. - Cellular outline packaging (aluminum / PVC) (2) - cardboard packs.
20 pcs. - Cellular outline packaging (aluminum / PVC) (5) - cardboard packs.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2014.
Antibodies to the brain-specific protein S-100 have antioxidant, antihypoxic, neuroprotective, anxiolytic effects. Modify the functional activity of the S-100 protein, which conjugates information and metabolic processes in the brain. They have a membrane-induced effect, causing a decrease in the amplitude and suppression of generation of the action potential: modulate synaptic plasticity in the limbic structures of the brain, the hippocampus, the reticular formation; contribute to the enhancement of inhibitory effects of GABA in the central nervous system. They exhibit the properties of the sigma 1 receptor agonist in vitro. Inhibit the processes of lipid peroxidation.
They have a normalizing effect on the integrative activity of the brain, which is manifested by a wide range of balanced psychopharmacological effects: antidepressant, ayxiolytic, neuroprotective, anti-asthenic, antiamnestic.
Antibodies to endothelial NO synthase increase the activity of the enzyme endothelial NO synthase, restore the production of endothelium nitric oxide (NO), eliminate endothelial dysfunction, have endothelioprotective effect, affect NO-dependent vasodilation.
Experimentally shown the stimulating effect of Divazy on reparative processes in the focus of ischemic brain damage.
The joint use of the components of the drug is accompanied by the enhancement of the neuroprotective activity of antibodies to the S-100 protein, the strengthening of the vegetative stabilizing effect, the normalization of the vegetative status, the synergistic effect of both components on neuronal plasticity, and, as a result, increased brain resistance to toxic effects; improves integrative activity and restores interhemispheric connections of the brain. contributes to the elimination of cognitive impairment, stimulates reparative processes and accelerates the recovery of CNS functions, increases mental performance, restores learning and memory processes, normalizes somatovegetative manifestations, increases cerebral blood flow. Divaza, like its constituent components, does not have sedative and muscle relaxant action, it does not cause addiction and addiction.
The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow to estimate the content of ultra-low doses of biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics of the drug Divaz.
- restoration of integrative activity of the brain with a wide range of organic disorders of the central nervous system, including those caused by neurodegenerative diseases, cerebrovascular (including ischemic) diseases, neuroinfections, craniocerebral trauma - as part of complex therapy;
- monotherapy of somatoform dysfunction of the autonomic nervous system.
Inside. At one time - 1 tablet (keep in your mouth until completely dissolved). Use 1-2 tablets 3 times a day out of the reception write. Depending on the severity of the condition, in the acute period, the frequency of admission can be increased to 4-6 times a day.
With pronounced organic lesions of the central nervous system, the duration of the course therapy can reach 4-6 months.
Possible reactions of increased individual sensitivity to the components of the drug.
- increased individual sensitivity to the components of the drug;
- the age of up to 18 years due to the lack of data on effectiveness and safety for this age.
PREGNANCY AND LACTATION
The safety of the use of Divaz during pregnancy and lactation has not been studied. If necessary, the drug should take into account the risk / benefit ratio.
APPLICATION FOR CHILDREN
Contraindicated for children under 18 years.
The composition of the drug includes lactose, and therefore it is not recommended for patients with congenital galactosemia, glucose malabsorption syndrome or galactose, or with congenital lactase insufficiency.
Impact on the ability to drive vehicles and manage mechanisms
Divaza does not affect the ability to drive vehicles and other potentially dangerous mechanisms.
In case of an accidental overdose, dyspepsia is possible due to the excipients included in the formulation.
There have been no incidents of incompatibility with other drugs to date.
TERMS OF RELEASE FROM PHARMACY
TERMS AND CONDITIONS OF STORAGE
In the dark place at a temperature of no higher than 25 В° C. Keep out of the reach of children. Shelf life - 3 years.